We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Considers Availability of Masked and De-Identified Data
FDA Considers Availability of Masked and De-Identified Data
June 7, 2013
The FDA is considering making more masked and de-identified safety and efficacy data from clinical and preclinical trials available to boost opportunities for innovative drug development.